We currently have two platforms in our drug development pipeline. We began a Phase 2 clinical study with PVS-RIPO in glioblastoma multiforme (GBM) in mid-2017 and expect to initiate pre-clinical studies in multiple other solid tumors. Initial pre-clinical and clinical studies indicate that solid tumor types accessible for intratumoral injection may also be optimal targets for PVS-RIPO, including melanoma and breast, prostate, colorectal, lung, pancreatic, ovarian and renal cancers. We expect to initiate a Phase 1 combination trial in melanoma in 2017. As funding allows, we plan to initiate Phase 1 trials in breast and prostate cancer.
Our ADC conjugate, D2C7-IT, is under evaluation in a dose escalation Phase 1 study in 24 recurrent GBM patients. It has been well-tolerated in 16 patients studied so far. We also have ADCs for additional tumors in pre-clinical development. Using different cytotoxic agents and linkers may lead to additional pipeline therapeutics for Istari Oncology. A wide variety of tumor types can be targeted by ADCs.
Learn more about our ongoing clinical studies with PVS-RIPO and ADC.